Bethesda Neurology

Clinical Trials

Dr. Katz is the DC-region primary investigator enrolling patients who have suffered non-arteritic anterior ischemic optic neuropathy (NAION) more than one year prior, with the hope of regenerating the damaged optic nerve fibers.  The trial is call REGENERA.

​

Dr. Katz is the DC regional principal investigator testing the first novel treatment for Leber's Hereditary Optic Neuropathy, a genetic disorder that causes bilateral optic nerve damage in young patients.

​

Dr. Katz was the DC-region primary investigator for an NIH sponsored US and Canadian clinical trial: Idiopathic Hypertension Treatment Trial (IIHTT).  IIH, also known as pseudotumor cerebri (PTC), is a disorder of elevated intracranial pressure of unknown cause.  The incidence is 225 new cases each year per 100,000 overweight women of childbearing age; it's incidence is rising in parallel with the obesity epidemic in developed countries.  It affect over 100.00 Americans.

​

For more information please review the website: www.nordicclinicaltrials.com